Saturday , November 25th , 2017  

ANGLE plc: Notice of AGM

GUILDFORD, SURREY—(Marketwired – Oct 20, 2017) –  ANGLE plc (AIM: AGL) (OTCQX: ANPCY)

AIM:AGL OTCQX:ANPCY

For immediate release 20 October 2017

ANGLE plc (“the Company”)

Annual Report and Accounts and Notice of AGM

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world–leading liquid biopsy company, announces that its AGM will be held at 2:00pm on Tuesday 31 October 2017 at ANGLE plc, 10 Nugent Road, the Surrey Research Park, Guildford, GU2 7AF.

The Annual Report and Accounts for the year ended 30 April 2017, posted to shareholders on 6 October 2017, together with the Notice of the Company's Annual General Meeting (“AGM”) are available for download on the Company's website, www.angleplc.com.

For further information ANGLE:

ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
 
   
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance – Adrian Hargrave, Simon Hicks, Kate Bannatyne
Corporate Broking – Alice Lane, Nikita Jain
+44 (0) 207 220 0500
   
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee
+44 (0) 203 705 9330
   
FTI Consulting
Simon Conway, Mo Noonan, Stephanie Cuthbert
Kimberly Ha (US)
+44 (0) 203 727 1000
+1 212 850 5612

Notes for editors

About ANGLE plc www.angleplc.com 

ANGLE is a world–leading liquid biopsy company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.

ANGLE's cell separation technology is called the Parsortix™ system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix™ is the subject of granted patents in Europe, the United States, Canada, India, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. Parsortix has a CE Mark for Europe and FDA authorisation is in process for the United States.

ANGLE has established formal collaborations with world–class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available here http://www.angleplc.com/the–company/collaborators/ 

The analysis of the cells that can be harvested from patient blood with ANGLE's Parsortix™ system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.

The global increase in cancer to a 1 in 3 lifetime incidence is set to drive a multi–billion dollar clinical market. The Parsortix™ system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug's effectiveness.

As well as cancer, the Parsortix™ technology has the potential for deployment with several other important cell types in the future.

ANGLE stock trades on the AIM market of the London Stock Exchange under the ticker symbol AGL and in New York on the OTC–QX under the ticker symbol ANPCY. For further information please visit: www.angleplc.com

This information is provided by RNS
The company news service from the London Stock Exchange

END

Share this post:

Recent Posts

Comments are closed.